Munro Partners Buys Shares of 126,836 Eli Lilly and Company $LLY

Munro Partners purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 126,836 shares of the company’s stock, valued at approximately $98,872,000. Eli Lilly and Company makes up approximately 3.1% of Munro Partners’ portfolio, making the stock its 10th biggest position.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Brighton Jones LLC grew its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $242,000. Steward Partners Investment Advisory LLC increased its stake in shares of Eli Lilly and Company by 3.6% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 74,811 shares of the company’s stock worth $61,788,000 after purchasing an additional 2,589 shares in the last quarter. Finally, Northwest & Ethical Investments L.P. raised its position in shares of Eli Lilly and Company by 9.4% during the 1st quarter. Northwest & Ethical Investments L.P. now owns 29,906 shares of the company’s stock worth $24,697,000 after purchasing an additional 2,579 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.8%

NYSE:LLY opened at $1,027.68 on Monday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a price-to-earnings-growth ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The stock has a 50-day simple moving average of $939.47 and a 200 day simple moving average of $820.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a research note on Monday, December 1st. CICC Research boosted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Finally, Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,121.90.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.